Table 2.
Radiotherapy characteristics (prescription dose and fractionization)
| Author/year | SRS (rate and characteristics) | FSRT (rate and characteristics) | WBI (rate and characteristics) |
|---|---|---|---|
| Id Said et al./ 2022 [21] |
78% (15–24 Gy/1 fraction) |
22% (24–32 Gy/3–5 fractions) |
– |
| Mills et al./ 2021 [22] |
60% (median dose 21 Gy (14–24 Gy)/ 1 fraction) |
40% (median dose 25 Gy (20–30)/ median fractions 5 (3–5)) |
– |
| Stumpf et al./ 2019 [20] | For RN lesions: median dose 20 Gy (18–25), median fractions 1 (1–5) | – | |
| Ippolito et al./ 2022 [23] | – |
100% (median dose 27 Gy (12–27)/ median dose per fraction 9 Gy (4–9)) |
– |
| Miller et al./ 2017 [13] |
100% (24 Gy (IQR 18–24)) |
– | – |
| Kim et al./ 2019 [24] |
100% (median dose 24 Gy (18–24)) |
– | – |
| Geraud et al./ 2017 [25] |
100% No details available |
– | – |
| Lebow et al./ 2023 [26] |
73.85% (59% 21 Gy/1 fraction, 13.8% 18 Gy/1 fraction, 1.05% other) |
26.05% (16.3% 27 Gy/3 fractions, 8.7% 30 Gy/5 fractions, 1.05% other) |
– |
| Khatri et al./ 2023 [27] |
72% (median dose 24 Gy (16–24)) |
28% (median dose 27 Gy (20–50)) |
– |
| Parsai et al./ 2019 [14] |
Dose according to RTOG 90–05 protocol: 18 Gy for tumours < / = 20 mm, 15 Gy for 21–30 mm; 12 Gy for 31–40 mm |
– | |
| Miller et al./ 2016 [28] |
100% (median dose 24 Gy (18–24)) |
– | – |
| Park et al./ 2022 [29] |
60.9% (1 fraction) (total median dose 20 Gy) (total mean dose 21.9 Gy) |
39.1% (5 fractions) (total median dose 20 Gy) (total mean dose 21.9 Gy) |
– |
| Koide et al./ 2024 [30] |
27.4% (18–22 Gy in 1 fraction) |
32.1% (17.3% 27–30 Gy in 3 fractions; 12.5% 30–35 Gy in 5 fractions; 2.4% 40 Gy in 8–10 fractions) |
40.5% (30 Gy in 10 fractions) |
Values are presented as percent or median (range), if not stated otherwise.
SRS stereotactic radiosurgery, FSRT fractionated stereotactic radiotherapy, WBI whole brain irradiation, Gy Gray, RN radionecrosis